Glaxo Wellcome's Second Act
Executive Summary
The company faces a series of challenges that attack head-on one of the most successful franchises in drug industry history. New approaches to treating ulcers, combination therapies that eradicate the bacteria that causes the disease rather than simply treat its symptoms, will likely lead to an overall decrease in the use of H2 antagonists. Even more threatening for Glaxo Wellcome is the pending genericization of Zantac (ranitidine). The question the company faces: will the same strategies that helpe
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports